Impact Factor
4.50
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
6.97
9,639 total citations
h5-index
118
h5 depth signal
Cited share
73.3%
1,071 of 1,461
Total citations
9,639
Citation footprint
Metric signal
6.60
External metric anchor
Self-citation
3.8%
366 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
6,451
United Kingdom
1,176
Canada
662
France
646
China
607
Citing Fields of Research
Antibiotic & Antibacterial Agents
2,572
Virology
2,151
HIV
1,590
Mycobacterial Diseases
786
Bacteriology
744
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
36,779
Articles tracked across the journal lifetime
Indexed publication set
1,461
1,071 cited publications
Last 12 months
757
63.1 publications/month
Open access share
34.7%
263 OA publications in the last year
Leading citing country
United States
6,451 citing publications
Leading citing field
Antibiotic & Antibacterial Agents
2,572 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v14,1992-
v14,1992-
Active Coverage
Research Focus & Classification
Indexed Subjects
Antibiotic & Antibacterial Agents
HIV
Mycobacterial Diseases
Virology
Fungal Pathogenesis
Issuing & Sponsoring Bodies
Contributor
Infectious Diseases Society of America
Broad Categories
Communicable Diseases
Antibiotic & Antibacterial Agents
Virology
HIV
Mycobacterial Diseases
Hepatitis
MeSH Descriptors
Communicable Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1093/cid/ciag661
Open DOI
Association Between Neighbourhood-level Antibiotic Utilization and the Rate of Community-Associated C. difficile (CA-CDI) Infection: An Ecological Study
Background: Despite reductions in hospital-associated Clostridioides difficile infection (CDI) incidence in Canada and the United States, the incidence of community-associated CDI (CA-CDI) has remained high. We sought to investigate whet...
02
03
DOI 10.1093/cid/ciag663
Open DOI
Ertapenem in Hypoalbuminemia: Methodological and Pharmacokinetic Considerations
04
DOI 10.1093/cid/ciag662
Open DOI
Empirical Antifungal Treatment of Critically Ill Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Bayesian Perspective
We reanalyzed 172 critically ill patients with influenza-associated ARDS in a Bayesian framework. Empirical mold-active antifungal treatment yielded a posterior median hazard ratio for influenza-associated pulmonary aspergillosis of 0.51...
05
06
DOI 10.1093/cid/ciag660
Open DOI
Randomized Trial Comparing Minocycline-EDTA-Ethanol Lock to Standard-of-Care Antibiotic Lock for Management of Central Line–Associated Bloodstream Infection
Background: Central line–associated bloodstream infections (CLABSI) cause substantial morbidity and mortality. Management often requires removing the infected central venous catheter (CVC) and inserting a new one. Effective catheter-salv...
07
DOI 10.1093/cid/ciag652
Open DOI
HIV and Cancer Progression: Interpreting Real-World Evidence
08
09
DOI 10.1093/cid/ciag656
Open DOI
Antibiotic Stewardship, Resistance, and Mortality in Vancomycin-Resistant Enterococcus: A Quasi-Experimental Study of Linezolid Restrictions
Background: Antibiotic restriction policies are intended to curb resistance, but their effects on resistance, timely treatment, and patient outcomes remain uncertain. We evaluated linezolid restrictions and whether vancomycin-resistant E...
10
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Vol. 19, no. 3 (1994)19950516 Notice published Printed on acid-free paper